ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Mangoceuticals Inc

Mangoceuticals Inc (MGRX)

2.315
0.005
( 0.22% )
Actualizado: 12:05:27

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Estadísticas y detalles clave

Último Precio
2.315
Postura de Compra
2.30
Postura de Venta
2.33
Volume Operado de la Acción
21,577
2.27 Rango del Día 2.3601
2.10 Rango de 52 semanas 16.80
Capitalización de Mercado [m]
Precio Anterior
2.31
Precio de Apertura
2.35
Última hora de negociación
12:01:42
Volumen financiero
US$ 49,799
Precio Promedio Ponderado
2.308
Volumen promedio (3 m)
4,110,586
Acciones en circulación
2,400,000
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-0.60
Beneficio por acción (BPA)
-3.84
turnover
731k
Beneficio neto
-9.21M

Acerca de Mangoceuticals Inc

Mangoceuticals, Inc. focuses on develops, markets, and sells various men's wellness products and services through a telemedicine platform. It offers erectile dysfunction products under the Mango brand name. The company sells its products through online website mangorx.com. Mangoceuticals, Inc. was i... Mangoceuticals, Inc. focuses on develops, markets, and sells various men's wellness products and services through a telemedicine platform. It offers erectile dysfunction products under the Mango brand name. The company sells its products through online website mangorx.com. Mangoceuticals, Inc. was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc. Mostrar más

Sector
Health & Allied Services,nec
Industria
Health & Allied Services,nec
Sitio web
Sede
Dallas, Texas, USA
Fundado
-
Mangoceuticals Inc is listed in the Health & Allied Services sector of the NASDAQ with ticker MGRX. The last closing price for Mangoceuticals was US$2.31. Over the last year, Mangoceuticals shares have traded in a share price range of US$ 2.10 to US$ 16.80.

Mangoceuticals currently has 2,400,000 shares in issue. The market capitalisation of Mangoceuticals is US$5.54 million. Mangoceuticals has a price to earnings ratio (PE ratio) of -0.60.

MGRX Últimas noticias

Mangoceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Bid Price Requirement

Dallas, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men’s health and...

MangoRx Announces Formation of Strategy and Alternatives Committee

Dallas, Texas, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men’s health and...

MangoRx Responds to and Refutes Recent Claims Made by Eli Lilly

Dallas, Texas, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men’s health and...

MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT AS PART OF NASDAQ COMPLIANCE PLAN

DALLAS, TX, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.075-3.138075313812.392.542.27861322.42264381CS
4-0.135-5.510204081632.452.652.11714312.42486002CS
12-1.8925-44.97920380274.20757.6592.141105864.28907181CS
26-1.405-37.76881720433.7216.82.148177236.01810817CS
52-5.635-70.88050314477.9516.82.127713115.82444649CS
156-60.685-96.32539682546364.0412.121732519.85861631CS
260-60.685-96.32539682546364.0412.121732519.85861631CS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
HCWBHCW Biologics Inc
US$ 1.8906
(541.75%)
429.98M
APLMApollomics Inc
US$ 0.2819
(193.95%)
1.06B
JWELJowell Global Ltd
US$ 2.9365
(50.59%)
12.47M
SINTSiNtx Technologies Inc
US$ 2.8501
(39.71%)
47.15M
SMCXDefiance Daily Target 2X Long SMCI ETF
US$ 27.222
(38.89%)
1.73M
QMMMQMMM Holdings Limited
US$ 2.09
(-71.49%)
3.23M
SGDSafe and Green Development Corporation
US$ 1.4857
(-44.15%)
327.85k
NGNENeurogene Inc
US$ 19.3801
(-43.85%)
1.13M
CMAXCareMax Inc
US$ 0.95
(-43.45%)
716.29k
GLXGGalaxy Payroll Group Ltd
US$ 3.50
(-30.28%)
385.44k
APLMApollomics Inc
US$ 0.2888
(201.15%)
1.06B
HCWBHCW Biologics Inc
US$ 1.8997
(544.84%)
430.05M
ELABElevai Labs Inc
US$ 0.023086
(4.46%)
203.36M
NVDANVIDIA Corporation
US$ 139.50
(-1.75%)
132.11M
SMCISuper Micro Computer Inc
US$ 22.38
(20.45%)
83.8M

MGRX Discussion

Ver más
KeepItRealistic KeepItRealistic 1 mes hace
$MGRX if company captures only 1/10th of one percent of that market, it gives you $49.3m in Revenues 😮

Let that SINK IN …

https://finance.yahoo.com/news/mangorx-addresses-49-3-billion-113000298.html
👍️0
KeepItRealistic KeepItRealistic 1 mes hace
$MGRX excellent exposure to capital

Dallas, Texas--(Newsfile Corp. - October 18, 2024) - Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling men’s health and wellness products via a secure telemedicine platform,, is pleased to announce it will be presenting at the Centurion One Capital 2nd Annual Bahamas Summit, which will be taking place at the exclusive Rosewood Baha Mar Hotel from Tuesday, October 22nd to Wednesday, October 23rd, 2024, in Nassau, Bahamas.

Jacob Cohen, Founder and CEO, is scheduled to present on Wednesday, October 23rd at 11:10 EDT. Jacob will also be fielding investor questions during the summit.

The Centurion One Capital 2nd Annual Bahamas Summit will feature public and private companies across various industries that will be given the opportunity to present to some of the most prominent venture capital, family office, private equity firms, high net worth individuals and institutional investors in the growth space attending from Canada, the United States, and abroad. For registration details, please click here.

Summit Details:

Event: Centurion One Capital 2nd Annual Bahamas Summit
Format: Presentations, Q&A, Panel Discussions and 1 X 1 Investor Meetings
Dates: Tuesday, October 22nd and Wednesday, October 23rd, 2024
Time: 9:00 AM EDT – 4:00 PM EDT
Venue: Rosewood Baha Mar Hotel

About Centurion One Capital

Centurion One Capital (“Centurion One”) is the premier independent Investment Banking firm dedicated to fueling the growth and success of growth companies in North America. With an unwavering commitment to delivering comprehensive financial solutions and strategic guidance, Centurion One is a trusted strategic partner and catalyst to propel issuers to unlock their full potential. Our team comprises seasoned professionals who combine extensive financial expertise with deep knowledge of various sectors. We take a proactive and results-driven approach, working closely with our clients to develop tailored strategies and execute transactions that maximize value and drive long-term success.

Centurion One - Empowering Growth. Driving Innovation. Partnering for Success.
👍️0
Invest-in-America Invest-in-America 1 mes hace
MGRX: However, the ONLY way this firm could make their stock SOAR in price, would be if they launch a NEW pill that is guaranteed to make ANY man's 'hot dog' 12-inches long, & 3-inches thick!!!!
👍️0
glenn1919 glenn1919 1 mes hace
MGRX.......................................https://stockcharts.com/h-sc/ui?s=MGRX&p=W&b=5&g=0&id=p86431144783
👍️0
Invest-in-America Invest-in-America 1 mes hace
MGRX: NICE!!!!!!
👍️0
tw0122 tw0122 1 mes hace
$3.65 + 37% Reverse split and “TRIM,” a compounded, oral dissolvable Tirzepatide tablet. Available for purchase at $399 per month, this new product offers patients an advanced and convenient alternative to injectable therapies.

Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men’s health and wellness products via a secure telemedicine platform, announces the release of its latest innovation, “TRIM,” a compounded, oral dissolvable Tirzepatide tablet. Available for purchase at $399 per month, this new product offers patients an advanced and convenient alternative to injectable therapies.
Tirzepatide, a dual GIP and GLP-1 receptor agonist, has gained widespread recognition for its effectiveness in promoting substantial weight loss by enhancing metabolic functions and controlling appetite. Clinical trials have shown that Tirzepatide can deliver weight reductions of up to 20% in obese individuals. The phase 3 SURMOUNT-1 clinical trial showed that a significant percentage of participants achieved weight loss of over 15-20% in just 72 weeks, marking it as a viable option and alternative for effective, long-term weight management?.

Further, in the SURMOUNT-4 trial, Tirzepatide not only helped patients achieve substantial weight loss, but it also helped patients maintain their progress over an extended period. After 88 weeks of treatment, patients experienced a total weight reduction of up to 25%, with nearly 90% maintaining at least 80% of their initial weight loss?.

MangoRx’s TRIM formulation now provides Tirzepatide treatment in an easy-to-use oral dissolvable tablet, eliminating the need for injections and enhancing patient convenience.

The launch of TRIM is a key strategic move for MangoRx, as the Company looks to strengthen its foothold in the expanding weight management sector. As demand for non-invasive, clinically proven solutions rises, we believe MangoRx is positioned to capitalize on this market growth.

Jacob Cohen, CEO and Founder of MangoRx, stated, “We are excited to bring TRIM to market, offering consumers a cutting-edge, oral alternative to conventional weight loss injections. TRIM’s introduction marks another significant step for MangoRx as we continue to innovate and meet the changing needs of patients. By launching TRIM, we are delivering a solution that enhances patient convenience without sacrificing efficacy. As demand for GLP-1-based treatments continues to climb, our telemedicine platform ensures that patients have access to safe, reliable options.”

According to a study performed by Roots Analysis, the global GLP-1 market is projected to grow from $49.3 billion in 2024 to $157.5 billion by 2035, with the obesity segment expected to capture the majority share by 2035, due to rising obesity rates and demand for effective treatments.

With the addition of TRIM, MangoRx now offers patients both Tirzepatide and Semaglutide options for weight loss treatments. Following the successful release of our Semaglutide-based oral dissolvable tablet branded as SLIM, patients can choose from two advanced, highly effective GLP-1 receptor agonists, each tailored to meet different needs in their weight management journey. Both products are currently listed on the MangoRx website and available with a doctor’s prescription, providing expanded access to cutting-edge weight loss solutions through its telemedicine platform.

👍️0
KeepItRealistic KeepItRealistic 1 mes hace
$MGRX 👀

https://x.com/keeprealistic/status/1847095691505791237?s=46&t=IJ2EAuutIm5R5c1kklP3-w

👍️0
KeepItRealistic KeepItRealistic 2 meses hace
$MGRX mega news below (huge market)

Market Correction incoming…

“Dallas, Texas, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men’s health and wellness products via a secure telemedicine platform, announces the release of its latest innovation, “TRIM,” a compounded, oral dissolvable Tirzepatide tablet. Available for purchase at $399 per month, this new product offers patients an advanced and convenient alternative to injectable therapies.

Tirzepatide, a dual GIP and GLP-1 receptor agonist, has gained widespread recognition for its effectiveness in promoting substantial weight loss by enhancing metabolic functions and controlling appetite. Clinical trials have shown that Tirzepatide can deliver weight reductions of up to 20% in obese individuals. The phase 3 SURMOUNT-1 clinical trial showed that a significant percentage of participants achieved weight loss of over 15-20% in just 72 weeks, marking it as a viable option and alternative for effective, long-term weight management?.

Further, in the SURMOUNT-4 trial, Tirzepatide not only helped patients achieve substantial weight loss, but it also helped patients maintain their progress over an extended period. After 88 weeks of treatment, patients experienced a total weight reduction of up to 25%, with nearly 90% maintaining at least 80% of their initial weight loss?.

MangoRx’s TRIM formulation now provides Tirzepatide treatment in an easy-to-use oral dissolvable tablet, eliminating the need for injections and enhancing patient convenience.

The launch of TRIM is a key strategic move for MangoRx, as the Company looks to strengthen its foothold in the expanding weight management sector. As demand for non-invasive, clinically proven solutions rises, we believe MangoRx is positioned to capitalize on this market growth.

Jacob Cohen, CEO and Founder of MangoRx, stated, “We are excited to bring TRIM to market, offering consumers a cutting-edge, oral alternative to conventional weight loss injections. TRIM’s introduction marks another significant step for MangoRx as we continue to innovate and meet the changing needs of patients. By launching TRIM, we are delivering a solution that enhances patient convenience without sacrificing efficacy. As demand for GLP-1-based treatments continues to climb, our telemedicine platform ensures that patients have access to safe, reliable options.”

According to a study performed by Roots Analysis, the global GLP-1 market is projected to grow from $49.3 billion in 2024 to $157.5 billion by 2035, with the obesity segment expected to capture the majority share by 2035, due to rising obesity rates and demand for effective treatments.

With the addition of TRIM, MangoRx now offers patients both Tirzepatide and Semaglutide options for weight loss treatments. Following the successful release of our Semaglutide-based oral dissolvable tablet branded as SLIM, patients can choose from two advanced, highly effective GLP-1 receptor agonists, each tailored to meet different needs in their weight management journey. Both products are currently listed on the MangoRx website and available with a doctor’s prescription, providing expanded access to cutting-edge weight loss solutions through its telemedicine platform.”





👍️0
KeepItRealistic KeepItRealistic 2 meses hace
“On October 1, 2024, the Company delivered an Advance Notice to the Purchaser and sold the Purchaser 2,000,000 shares of common stock pursuant to the terms of the ELOC for $0.26 per share for a total of $521,016, net of fees, discounts and expenses”
👍️0
KeepItRealistic KeepItRealistic 2 meses hace
$MGRX company has been selling shares which explains the retrace

https://www.otcmarkets.com/filing/html?id=17875545&guid=9OL-kaoudyTyDVh
👍 1
Penny chatter Penny chatter 2 meses hace
Looks like this guy is just a promoter
👍️0
power11 power11 2 meses hace
AS THEY SAY IN ITALIAN : PUMPO AND DUMPO !!!!
PURE DOG SHIT WRAPPED IN CAT SHIT
👍 1
TrendTrade2016 TrendTrade2016 2 meses hace
dilute dilute...drop like a rock into open
👍️0
glenn1919 glenn1919 2 meses hace
MGRX..............................https://stockcharts.com/h-sc/ui?s=MGRX&p=W&b=5&g=0&id=p86431144783
👍️0
FROZENFLAME FROZENFLAME 3 meses hace
Thin L2 !
👍️0
FROZENFLAME FROZENFLAME 3 meses hace
It’s moving, waiting on more volume !
👍️0
mining101 mining101 3 meses hace
Big week upcoming
👍️0
glenn1919 glenn1919 4 meses hace
MGRX..........................https://stockcharts.com/h-sc/ui?s=MGRX&p=W&b=5&g=0&id=p86431144783
👍️0
Penny2Dime Penny2Dime 4 meses hace
Nice!
👍️0
KeepItRealistic KeepItRealistic 4 meses hace
$MGRX huge

https://x.com/nxtplse/status/1816808590138568792?s=46&t=IJ2EAuutIm5R5c1kklP3-w

👍️0
mining101 mining101 4 meses hace
New highs are in sight
👍️0
KeepItRealistic KeepItRealistic 4 meses hace
$MGRX more solid news

https://ca.finance.yahoo.com/news/mangorx-initiates-efficacy-studies-patented-121500395.html
👍️0
KeepItRealistic KeepItRealistic 4 meses hace
$MGRX game changer

https://stocktwits.com/RandySays/message/580033852

👍️0
KeepItRealistic KeepItRealistic 4 meses hace
$MGRX like what I heard…

👍️0
KeepItRealistic KeepItRealistic 4 meses hace
$MGRX keep your 👀 on it for follow up on …

https://finance.yahoo.com/news/mangorx-introduce-oral-semaglutide-tirzepatide-123000451.html

“MangoRx plans to have the products available for customers on the company’s telemedicine platform in the beginning of the 3rd quarter with ‘Slim’ and ‘Trim’ competitively priced at $299/month and $399/month, respectively. MangoRx is committed to advancing the treatment of obesity and related conditions and is dedicated to improving the lives of patients worldwide.”

3rd Qtr started July 1st

This was the news that pushed it past $1
👍️0
mining101 mining101 4 meses hace
Break .50 soon
👍️0
glenn1919 glenn1919 4 meses hace
MGRX........................https://stockcharts.com/h-sc/ui?s=MGRX&p=W&b=5&g=0&id=p86431144783






👍️0
Invest-in-America Invest-in-America 4 meses hace
MGRX: For their next "news", maybe MGRX can get a pre-fight promo going to the effect that both Jake Paul & Mike Tyson use their stuff!!
👍️0
mining101 mining101 4 meses hace
Rebound to 1
👍️0
Zardiw Zardiw 4 meses hace
I'm wondering if you're pissed off at me for some reason.....can't PM........but whatever it is, I'm sorry if I did/said anything that you didn't like.....

Hans@DDAmanda.com
760 702-2009

Z
👍️0
Invest-in-America Invest-in-America 4 meses hace
MGRX: Might be the kind of news this Firm has long needed. (I.e., no more silly promos, ads, etc. ---- now, serious business.)
👍️0
PinkPennies PinkPennies 4 meses hace
MGRX nice news https://finance.yahoo.com/news/mangorx-announces-strategic-partnership-expansion-121500806.html
👍️0
valleybenedetto valleybenedetto 5 meses hace
Mango written up by JP Morgan Fund!

https://athletechnews.com/jp-morgan-targets-weight-loss-drugs-with-500m-fund/?s=09
👍️ 1 💯 1
Golden Cross Golden Cross 5 meses hace
$MGRX MangoRx to Introduce “MOJO” Pharmaceutical Compounded Formula Featuring Enclomiphene Citrate and Pregnenolone for Treatment of Low Testosterone and Male Hormone Imbalances https://www.stocktitan.net/news/MGRX/mango-rx-to-introduce-mojo-pharmaceutical-compounded-formula-xetrg1zk54sn.html
👍️0
Carjockey2 Carjockey2 6 meses hace
Haaaaa..

I am the new crypto coin gal..

Lol
👍️0
valleybenedetto valleybenedetto 6 meses hace
Trade em up. No more marriages
👍️0
Carjockey2 Carjockey2 6 meses hace
Nice news but I'm done with this one.

👍️0
valleybenedetto valleybenedetto 6 meses hace
Nice news today. Partnered with CrakMedia..same firm that brought BlueChew to 200m revs
👍️0
Carjockey2 Carjockey2 6 meses hace
Again...

Don't include me on your posts like you did all day today..

Does that work for you..works for me..

Cyber stalking is illegal...

Back to your 4 jobs you go..

👍️0
crowin crowin 6 meses hace
Again my point that everything is about you!

Get back with the family, they miss you!


Please keep your post about MGRX.
👍️0
Carjockey2 Carjockey2 6 meses hace
LMAO

You have had time to stalk me for 10 years..YES 10 years..


I am happily retired..

No 4 jobs for me..

Follow the right traders you won't have to work 4 jobs..

After following me for 10 years you should be happily retired with your family what have you been doing wrong







👍️0
crowin crowin 6 meses hace
I Have a life and do not hang out around here allday, just mornings.

What is wrong with that ?

Take care of the family like i do.

4 business and family is my priority...
Whats yours?
👍️0
crowin crowin 6 meses hace
Everything you post is about you. Stop it!

You missed out today for a quick buck.

Whats next?

Stop stalking me when I make money without you!
Go and enjoy the Grand baby!

Granny, will you please focus on me and not IHUB!

I miss you granny......
👍️0
Carjockey2 Carjockey2 6 meses hace
If you I really owned shares here you wouldn't be posting five times to me on a board you'd be celebrating, so I guess we know what's up..

We all know you stalk me but that's even crazy..
👍️0
Carjockey2 Carjockey2 6 meses hace
Lolzzzz

Awesome day here..

$MGRX


What's weee??

This was your last post in February..lol

Reverse Stock split to risky here

Silly bird.. is it difficult pretending you own shares of something you hated when it runs???
👍️0
Carjockey2 Carjockey2 6 meses hace
Great day everybody congratulations..

$MGRX got a bona..

😉
👍️0
Invest-in-America Invest-in-America 6 meses hace
MGRX: Are my MGRX shares 'rising-from-the-ashes' now, following a rather disappointing Close today??? (At 32% UP in the Post-M right now, might be so.)
👍️0
Invest-in-America Invest-in-America 6 meses hace
MGRX: Hey "Invest-in-America", CLOWN!! Why don't you flush your pet PUSSYCAT down that toilet, FOOL!!! (Which is likely the ONLY 'pussy' you ever got, STUPID!!) WHY??? Because our MGRX COMEBACK is gonna make Tom Brady's look like those stupid 'BUCKS' of Florida never even scored ONE POINT in that game!!!
👍️0
Invest-in-America Invest-in-America 6 meses hace
MGRX: See today's final 'CHART', below!!

👍️0
Invest-in-America Invest-in-America 6 meses hace
MGRX: Come on, you dead-cat, BOUNCE!!! For the sake of us BIG-FAT-&-GREASY Amerikanos!!! And heck, you have one pill to make mens' DICKS big & fat --- and now another pill to make their OBESITY-BODIES "slim & trim"!!! Why not do BOTH in just one, tasty, fat pill???!!!

////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////
And see BELOW, what my own 'Personal Financial Planner' said to me early today, when I asked him what he thought about me tossin' some bucks at MGRX stock ---
👍️0